Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bloomber/Company files: confused ?
a list of pdf docs have been uploaded on 8th of december: they are the documents and management relations all relative to 2016 FY results.
????? ????
Manipulation - reading recent posts it seems that it is becoming more and more concrete the hypothesis that I started stressing over a year ago: this stock is strongly manipulated and not just shorted.
1 - even when the company had a positive momentum in delivering something we had more than 1 occasion where a good news was shorted...the same day I mean; usually a very big spike in a small cap is shorted. That is my very first point: you short a big spike in price not the positive announcement, the difference is in the timing of the short and the price level of the short opening...and it is a world of difference
2 - the manipulation is something "personal" vs Odidi; someone/Group developed personal anger due to not being involved in the ipci story - not having his/its terms accepted; from that moment it was decided to destroy the share price to finally get in control of the company for the cheapest possibile amount
3 - the manipulation has been so far succesfull thanks to: a) the Odidi going wrong big time on Rexista (plus the AdComm ambush where an expert team would never went so imprepared)b) mr Odidi not partnernig everything he should have wayback. Therefore we now have a company unable to deliver being manipulated. an EASY game even easier due the ridicoulous floating and mkt cap.
4 - when a listed company doesn't understand that market forces could play a dramatic role in the way they are going to conduct business it becomes an ideal candidate for the manipulation
5 - I believe that since FDA issued CRL on Rexista the stock has been just washed downward, and not net shorted. there are too many fake transactions.
6 - please, those attending the meeting, the company is risking of being took over for the cheapest conceivable amount
7 - those f..ing b...rds who are manipulating are reading here, sometime I believe even writing here. This is for u: go to hell!
Total TRX count - Quetiapine Fumarate ER - weekly
MALLINCKRODT PH 725 481 708 744 726 699
Total 21.59k 17.95k 20.35k 20.36k 20.58k 20.12k
Total TRX count - DEXMETHYLPHENIDATE HCL ER- weekly
PAR PHARMA 6.34k 4.90k 6.15k 6.37k 6.17k 6.24k
5 and 40mg generic Focalin XR numbers
dexmethylphenidate HCL ER - TRX Count
2015 Total: 1.28M 5Mg: 149K(11.6%) 40Mg:85K (6.6%)
2016 Total: 1.79M 5mg: 185K(10.3%) 40Mg: 104K (5.8%)
YTD Total (october): 1.68M 5mg:163K (9.8%) 40mg (93K)5.5%
TRX Dollars
2015 Total 328Mln 5mg:38.6mln (11.7%) 40mg:21.4Mln (6.5%)
2016 Total 465Mln 5mg:45.8mln (9.9%) 40mg: (5.6%)
YTD Total (october): 438Mln 5mg: 39.4(9%) 40mg: 23.4 (5.3%)
based on current mkt penetration and % split between ipci and PAR for other doses we could try to determine the impact coming for the 2 new doses
wimusky, wmike, tilator, doog,
good reading your recent discussions.
- on the shorting: the point to be stressed during the meeting has not to be the legal aspect, but that this manipulation has the objective to make the company took aver for peanuts; therfore share price has an enourmous importance and has to be defended at some point, otherwise go private
- on the CRL issued for ANDAs; I believe that is material information which should by law shared with market partecipants; it is not acceptable they don't tell us where they stand for each of their drugs.
- tilator, this negotation you have been having for Gluco...they sound either idiots or unwilling to have ANY kind of deal (reasons Beyond my reach).
- the BoD has to be dismissed; a Group of lazy people which are assisting Odidi in his ineptitude. This is the main reason I am hoping for Armistice to reach 10-15% of ipci and then start forcing the change.
I believe mr Boyd could be the key; if he sees what we see (a lot of potential but with very poor management, to be generous) then we have a powerful ally. his investment style should suggest he already perceived the dicotomy opportunity-bad managers and started to act accordingly.
He could succeed or not, but he has the leverage necessary for the change otherwise I don't see happening.
Angelo, It looks like we have a net buyer today...I bet Friday will see Armistice incremented.
Wim, if you are correct looks like something very important to me;
it means that somebody who sees the potential and understands Odidi's inability to deliver could try to get in control.
I am not thinking of a takeover, but taking control of the BoD and offering Odidi a life lab profession, nothing else...take it or leave it.
If patents along with technology stay with the company, then this furtherly proves how the man doesn't really get it: he could loose company control for a small fraction of the money ipci was valued just 6 months ago.
This is a possibility that becomes the more concrete the more they keep on ignoring markets forces.
The activist scenario (just like something the happens from time to time):
- wash short the stock
- accumulate while in the process
- get voting control
- get rid of Odidis management
- if necessary reverse split for NASDAQ compliance
- partener/sell the assets
- walk away rich
stronly agreed...2 years from now either ipci is dead or ANDAs will represent somthing of secondary importance
Reason of my question is simple: if patents issued to IPCI are "enough" to get things rolling, then someone could even think of taking control of the Board and relegate Odidis to the lab.
He wouldn't agree but then he will accept due to his creation potentially goin on without him.
Just speculating on my side, but trying to understand if someone like Boyd could at some point (NOT NOW) force Odidis.
Intellectual Property
who is entitled to the rights deriving from all IP issued, mr Odidi or IPCI ?
Armistice Capital up from 1636000 shares to 1816000 shares (or 5.2% of shares out)
Wim and Angelo, let's see if mr Boyd has better insights than ourself; it is a small bet for his fund, but that is the kind of guy who doesn't like losing money.
Let's see if he decides to increase again...likely he would then try to influence the BoD...he is an ACTIVIST by nature.
Regarding possible negotations: we know for sure that there is a legal procedure with Purdue, something which is by definition set up to find possible Agreement before the court gets the process in its full hands (Samsa, pls correct me if I am wrong). Likely insider buying it is not allowed during this period.
Regarding Rexista AdComm and filing: it is clear it was an ambush; FDA and IPCI already agreed a path towards intravenous approval. IPCI fault was: 1) not having a partner on its side, helping with the process and lobbying 2) not having a pharma lawyer at the AdComm 3) not having someone with presentation skills at the AdComm.
IPCI is currently a bunch of people with very low business acumen and even less financial markets dynamics comprehension.
But, there is a but...they still have 6-9 months to change/deliver on many fronts:
if that happens I would expect the market cap to be at least 100Mln, which could be reached via an Agreement with Purdue alone.
My expectations are right now pessimistics, but still has tiny hopes.
Samsa,
we have to admit that IPCI is becoming a very good example of the importance of adapting the strategy of a company to the oustide context...and what happen if you're not going to.
But what is becoming suicidal is not getting the importance of share price valuation (which is by definition company's valuation attributed by the market).
Now it is clear that they don't understand (!!) the importance of not diluting when you are under attack, the impotance of reducing floating when you have recurring naked shorting happening, and so on.
it is now very clear that they (Odidi and BoD) don't perfectly get the sense of financial markets and the concept of being listed.
I don't know what will be our future, but ipci management whould deserve to see the shares drove down so that they will end up being took over with just 10mln of market cap ...ooppsss...maybe I just revelead the inner secret of those behind the manipulation game.
SadSadSad
One more thing: if ipci price goes to ...well much lower Odidi will Likely loose not so much, given his golden compensation pack over this years.
But someone could start playing a different game with him: he will lose his honour and respect even as a scientist....incapable to deliver in all his promises about his science.
I believe Samsa is expressing the concept himself and myself shared for many times in the past:
Company has to,must deliver and issue PR
BUT
Share price action has been disconnected many times with company's progress-only clear exception post AdComm.
So when you have positive news and price going down, for several times in two years, then you have a path.
You cannot say, positive PR and we go down because company doesn't deliver or whatever.
We have to accept it: ipci is very badly managed, but those rare positive developments have caused the price to go down.
We have someone with a mission and the company not caring about share price is making us in a very very dangerous situation.
We should have buybacks, Odidis converting the debenture, floating reduced via partners getting onboard....pls share with Patient.
I believe it is now becoming a possible outcome. If armistice capital decides to exit we go to 0.3 in one day.
But shares price is something they can't control... beyond redicoulous.
Guys this is going to end badly. Company doesn't care about share price (what a surprise) and someone wants ipci at 15mln mkt cap or lower. This is the most disgusting stock I have ever seen
It was on Bloomberg this early morning European time
agreed.
but when you see shorting in corrispndence with positive news you get the feeling something bigger is behind the scenes...and I mean negative.
this stock is below the radar, super tiny float and daily volume...
I have the feeling of a flash crash about to happen. strongly hope to be wrong, but 0.80 likely to be crashed and headed for 0.75
"The only 100% proven way to drive out manipulation and shorting in any stock(especially this one)...is to deliver sustained positive material results that constantly raises the valuation metrics that the market masses in general will apply here. "
yes
yes
yes
100% agreed...they have to deliver and communicate...not saying they can't do anything.
they seem to be disconnected with the markets; at ipci it is not clear the difference between being a listed company and a private one.
they cannot do anything about the share price and shorts Attacks?
guys, sum it with the positive news-negative day behaviour and I wonder how we will avoid delisting next year .
Only a big partnership, which to me is not going to happen due to Odidi deatchment with real world.
question to this msg board:
which could seriously be the advantage for Purdue of having IPCI delisted, if any ?
For those attending the meeting...pls do show Mr Patient this sick behaviour.
It was repeated several times over the last 2 yrs.
Good news red day relatively heavy volume.
Only one explanation: manipulation.
This stock was almost dead, tight range and super tiny volume...then a good news after months of nothing..and we go down on heavy volume?
There's something going on and we have to act...or the delisting will become a reality. By the way... could it be the real objective of the manipulation? For whatever reason to get a delisting??
Disgusting...as always
This is the IPCI we know...good news (big, small, whatever)..and we go down ! what a joke
don't dispute that...everybody is free to make his informed decisions.
my point is: why opening a discussion about bitcoin into a biotech message board; ok when talking about another stock as a comparison for whatever metric or strategic path. but bitcoin is a completely different realm
ending here my OT
Tek, please...this is way too off topic.
Bitcoin and cryptocurrencies represent a part of the future, but right now they are in a bubble. ending Tomorrow, in 5 months, or 2 yrs...nobody knows, but I believe history demonstrated that there is nothing which price could go up indefinetely.
tech companies in 2000 (they changed the world, yes, but prices went down sharply before going up again)
gold, oil, ...tulipans ...LoL
think about selling IPCI and putting that money in bitcoin ?
you could reccover everything in one week, or halve it...
JMHO
"Exactly ten days ago I sent mr. Akyempon an email asking someone to make me an offer about Glucophage. I would like to buy 20.000 packages each strength having 100 capsules in each package. "
Tilator, I suggest you escalate to the BoD and keep note of everything.
I am not sure if there could any kind of infrangiments towards shaholders' interest when not even considering a commercial proposition for a product the company says it finds difficult to commercialize.
Let's put increasing pressure on this bunch of incompetent arrogants
TRX Count - Dexmethyl.HCL ER - by week
PAR: 11/17: 6.15K 11/10: 6.37K 11/03: 6.17K 10/27: 6.24K
TOtal count: 43.4K 43.7K 42.6K 42.6K
Total prescriptions manufacturer's benchmark sales dollars
PAR: 11/17: 1.28M 11/10: 1.32M 11/03: 1.27M 10/27: 1.3M
TOtal count: 9.4M 9.5M 9.2M 9.3M
TRX Count - Quietiapine Fumarate ER - weekly
Mallinck: 11/17: 708 11/10: 744 11/03: 726 10/27: 699
TOtal count: 20.35K 20.36K 20.58K 20.12K
Total Prescriptions Manufacture's Benchmark sales dollars
Mallinck: 11/17: 24.6 11/10: 26.9 11/03: 26.6 10/27: 26.5
TOtal count: 3.8Mln 3.9Mln 4.75Mln 4.7Mln
we are not going anywhere with these data
while mr Odidi is enjoying his yellow Lambo all over shopping streets for the black friday, I just gave a lazy look at the ipci shareholders.
some tiny movements fere filed as of 30 of september, which I didn't notice given the major news was Armistice new stake as of 10of Oct:
First Foundation added 113K shares, now it holds 1.7%
Susquehann sold 105K, now it holds 0.1%
ART Advisors entered with a new position of 52.8K shares, 0.15%
Verity Asset Management open a new one of 30K, 0.09
I personally own more shares than many of the instituionals appearing on the shareholders list...so I am well aware of the sadness of this data.
Angelo, see my previous post.
Fred used a different filter, inconsistent with previous filtering. That's way you have those numbers.
I think the NRX Dollars By Payment Type is a filter we never used before.
I have to the conclusion that in terms of dollar sales we could use the total benchmark's manufacturer dollar sales filter.
And Wim, Yes by the numbers Astra is making the major revenue on the Branded Seroquel, where it is showed as the only seller. Likely they got some form of generic as well
Not available until two hours ago. Now I am no more in the office. Anyway expect them to be in line with previous week.
We need the company to deliver on other fronts.
Samsa, I agree we have to stick with TRX count.
It is somewhat frustrating we have to reverse engineer the numbers, given the company doesn't communicate revenue split and not even a guidance (a range). They don't bother to say that maybe starting sales will encounter this kind of dicculty or that.
IPCI should just be a private company; they need a major reshuffle in board and management. I strongly agree with Wim that the Sales Manger we have is an idiot just waiting for the phone to ring.
why not something like this, mr Odidi ?
SCYNEXIS Appoints Scott Sukenick as General Counsel- Announces Inducement Grant Under NASDAQ Rule 5635(c)(4) -
PR Newswire
JERSEY CITY, N.J., Nov. 16, 2017
JERSEY CITY, N.J., Nov. 16, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of Scott Sukenick, J.D., as General Counsel, effective November 15, 2017. Mr. Sukenick will be responsible for leading the Company's corporate strategic and tactical legal initiatives, including intellectual property and compliance. Mr. Sukenick will report to Marco Taglietti, M.D., SCYNEXIS' President and Chief Executive Officer.
"Scott brings invaluable legal and strategic expertise to SCYNEXIS as we continue to advance our lead asset, SCY-078, through clinical development," said Marco Taglietti, M.D., SCYNEXIS' President and Chief Executive Officer. "We are fortunate to have someone of his caliber, with a combination of strong scientific acumen and a broad range of legal experience in the life sciences sector. I welcome Scott to our wonderful and dynamic team and look forward to our collaboration with him to make SCYNEXIS a success."
Mr. Sukenick joins SCYNEXIS after over a decade addressing a diversity of legal challenges faced by innovative life sciences companies at all stages of development. Mr. Sukenick most recently worked at Cooley LLP, where he focused on life sciences litigation and strategic intellectual property management. Prior to that, he worked at Patterson Belknap Webb & Tyler LLP, where he primarily represented pharmaceutical and medical device companies in patent litigation. He started his career at Simpson Thacher & Bartlett LLP, where his practice focused on complex commercial litigation and intellectual property transactional matters. Mr. Sukenick is a registered patent attorney. He obtained a B.S. in Biology and a B.A. in Chemistry from Duke University and a J.D. from Harvard University.
In connection with this appointment, on November 15, 2017, Mr. Sukenick was granted an option to purchase 160,000 shares of SCYNEXIS common stock, at a per share exercise price of $1.75, the closing trading price on November 15, 2017. The option has a ten-year term, with one-fourth of the shares subject to the option vesting on the one-year anniversary of the date of grant and the remainder vesting in equal monthly installments for thirty-six months thereafter, provided Mr. Sukenick continues to provide service to SCYNEXIS. The stock option was granted pursuant to SCYNEXIS' 2015 Inducement Award Plan, which was adopted by the company's board of directors in March 2015 under Rule 5635(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
Sure Trader - $4.95 P ? where does it come from ? from your reply it looks like it was in my initial message, but I didn't put in there.
anyway unfortunately I don't have any info about substitution nor geographic split.
AstraZeneca data
just to complete what started Yesterday:
under Seroquel XR - Total prescriptions Manufacturer's Benchmark Sales dollars
There is only ASTRAZENECA selling around 5mln per week, more or less stable over the last 4 months
monthly date
10/31:22Mln 09/30:22Mln 08/31:24.6Mln 07/31:25.5 06/30: 29 05/31:33.6M
Samsa but someone else in the past propose to use the prescriptions number as a more reliable data, and I agree with this approach. On this note we have
Seroquel XR: monthly TRX Count
There is only ASTRA
10/31: 30.1K 09/30: 30.4K 08/31:34K 07/31: 35K 06/30:40.8k 05/31: 47.5K
Quitapine Fum ER: monthly TRX Count
10/31
PAR:30.7K Acc: 29K Tru: 13K Astra: 10.8K Mall 3.3K Lup 1.9K
09/30
PAR:30.7K Acc: 27.3K Tru: 11.7K Astra: 11K Mall 2.6K Lup 0.4K
08/31
PAR:34.4K Acc: 27.6K Tru: 11.3K Astra: 12.5K Mall 1.7K Lup --
07/31
PAR:35.9K Acc: 24.1K Tru: 9.8K Astra: 11.5K Mall 0.6K Lup --
Thanks. LoL.
I just tried to look at the only filter still unsed, from those that the Bloomberg-Symphony database offer.
I am not aware of the meaning of the "Total prescriptions Manufacturer's benchmark sales dollar" .
Since I am trying to help everybody here with the info I have access to, I feel somewhat uncomfortable if the numbers have not the right cut/interpretation.
Therefore I tried this further option; if we look at total annual numbers they seem to make sense, considering 1.2bln sales of Seroquel XR before the generics have been hitting the market.
All I can say is that everybody should become aware that generics will serve IPCI just as a survival buffer.
If the unfitting management doesn't deliver on the NDAs and Podras tech..we are just dead. They have been sleeping over the last several months, we are getting close to a critical point.
Bunch of incompetents
Bloomberg data - Symphony - here is my attempt
let's try (I would say let's cry) with the TRX MBS $:
Total prescriptions manufacturer's benchmark sales dollars
Quetiapine Fum ER
weekly
11/03 Par:3.5M Acc:969K Truph:129K Astra:85K Lup:75K Mall:27K
10/27 Par:3.5M Acc:932K Truph:125K Astra:86K Lup:63K Mall:26K
10/20 Par:3.3M Acc:924K Truph:127K Astra:88K Lup:45K Mall:25K
10/13 Par:3.5M Acc:969K Truph:129K Astra:85K Lup:75K Mall:27K
monthly
10/31 Par:15.1M Acc:4.1M Truph:549K Astra:393K Lup:231K Mall:119K
09/30 Par:15.2M Acc:3.8M Truph:495K Astra:396K Lup:54K Mall:99K
08/31 Par:17.5M Acc:3.9M Truph:483K Astra:3.4M Lup:-- Mall:64K
07/31 Par:17.8M Acc:5.8M Truph:439K Astra:6.8M Lup:-- Mall:24K
06/30 Par:21.8M Acc:7.2M Truph:342K Astra:5.6M Lup:-- Mall:8K
Quetiapine Fum ER
TOTAL YTD: 333.8M
2016: 65.6M
2015: --
SEROQUEL XR
TOTAL YTD: 304.3M
2016: 1.1Bln
2015: 1.2Bln
2014: 1.2Bln
It was a direct competitor before Odidi driving us into the AdComm debacle